Volume 38 Issue 10, October 2020

The Chan Zuckerberg Biohub is both an institute and an academic network devoted to accelerating research via cutting edge technologies and open science. Its focus on single-cell analysis and infectious disease has placed it front and center in the pandemic.

Voluntary pledges to make intellectual property broadly available to address urgent public health crises can overcome administrative and legal hurdles faced by more elaborate legal arrangements such as patent pools and achieve greater acceptance than governmental compulsory licensing.

Recent patents related to methods for the mass production of exosomes and engineering of exosomes for therapeutic use.

A hybrid CRISPR–Cas9 variant is able to specifically and efficiently target a larger proportion of the genome.

Mass spectral fragmentations of lipids across 117 lipid subclasses are presented in a lipidome atlas.

Testing sewage for the novel coronavirus reveals epidemiological trends.

SARS-CoV-2 is reliably detected in nasal swab samples using mass spectrometry and machine learning analysis.

Of 12 serology assays tested, four detect antibodies in more than 80% of patients with COVID-19.

The location of genetic and epigenetic elements in mammalian nuclei is measured by gradual DNA fragmentation.

The T-cell response to tuberculosis is examined by clustering T-cell receptor sequences to identify shared specificities, along with whole-genome antigen screening.

Sequencing wild relatives of millet identifies genes that regulate yield and harvesting traits.

A national network of medical technology incubators provides experiential training for the next generation of medical entrepreneurs and enables creation of innovative technologies for pressing clinical needs.

Recent moves of note in and around the biotech and pharma industries.